Healthcare · NIFTY 500
Gland Pharma Limited
₹3,385.90 +51.80 (+1.55%) Updated 16 Nov, 8:14 pm IST
Today
- Open
- ₹3,350.80
- Prev close
- ₹3,334.10
- Day high
- ₹3,429.00
- Day low
- ₹3,341.00
- Volume
- 4.19 L
- Value traded
- ₹142.01 Cr
- Upper circuit
- ₹4,000.90
- Lower circuit
- ₹2,667.30
- 52W high
- ₹3,385.90
- 52W low
- ₹1,573.60
- 1 month
- +8.73%
- 6 months
- +54.60%
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Quarterly results
Results for each quarter
Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Revenue · QoQ (vs last quarter)
Revenue · YoY (vs a year ago)
Net profit · QoQ (vs last quarter)
Net profit · YoY (vs a year ago)
EPS (₹) · YoY (vs a year ago)
| ₹ Cr | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 | 1,834 |
| Other income | 37.4 | 42.1 | 51.4 | 59.7 | 58.5 | 44.0 | 57.5 | 84.2 | 63.2 | 111 | 61.2 | 69.0 |
| Total income | 1,583 | 1,580 | 1,453 | 1,465 | 1,443 | 1,469 | 1,563 | 1,571 | 1,759 | 1,854 | 1,861 | 1,903 |
| Raw material | 464 | 575 | 462 | 486 | 437 | 588 | 557 | 558 | 530 | 594 | 588 | 641 |
| Purchases | 6.4 | 6.8 | 6.6 | 2.7 | 2.1 | 3.1 | 0.9 | 1.9 | 1.5 | 2.3 | 1.9 | 3.1 |
| Employee cost | 345 | 352 | 356 | 330 | 343 | 373 | 408 | 385 | 424 | 412 | 444 | 412 |
| Other expenses | 244 | 228 | 218 | 204 | 219 | 216 | 209 | 234 | 260 | 227 | 243 | 268 |
| Total expenses | 1,299 | 1,281 | 1,235 | 1,209 | 1,143 | 1,181 | 1,250 | 1,287 | 1,372 | 1,348 | 1,427 | 1,472 |
| Operating profit | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 411 | 513 | 489 | 484 |
| OPM % | 23.1% | 23.3% | 18.9% | 21.1% | 26.0% | 24.4% | 24.4% | 21.1% | 24.2% | 29.4% | 27.2% | 26.4% |
| Finance cost | 5.3 | 10.0 | 5.6 | 6.1 | 22.8 | 7.5 | 11.5 | 7.8 | 3.9 | 10.0 | 4.4 | 7.1 |
| Depreciation | 105 | 92.6 | 92.0 | 93.8 | 96.3 | 95.8 | 101 | 106 | 108 | 109 | 111 | 115 |
| Exceptional items | — | — | — | — | — | — | — | — | -24.3 | — | — | — |
| Profit before tax | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 | 431 |
| Tax | 91.3 | 106 | 74.5 | 93.2 | 94.6 | 102 | 97.3 | 100 | 101 | 139 | 118 | 140 |
| Net profit | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 | 291 |
| Profit to shareholders | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 | 291 |
| EPS (₹) | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.23 | 19.22 | 17.62 |
Profit & loss
Results for each year
6 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
Revenue · YoY (vs a year ago)
Net profit · YoY (vs a year ago)
| ₹ Cr | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | 3,463 | 4,401 | 3,625 | 5,665 | 5,617 | 6,431 |
| Other income | 135 | 224 | 240 | 170 | 214 | 316 |
| Total expenses | 2,263 | 3,006 | 2,754 | 4,702 | 4,767 | 5,258 |
| Employee cost | 311 | 339 | 403 | 1,257 | 1,402 | 1,629 |
| Operating profit | 1,302 | 1,510 | 968 | 1,333 | 1,269 | 1,605 |
| OPM % | 37.6% | 34.3% | 26.7% | 23.5% | 22.6% | 25.0% |
| Finance cost | 3.4 | 5.2 | 7.4 | 26.2 | 42.0 | 33.3 |
| Depreciation | 98.8 | 110 | 147 | 345 | 378 | 424 |
| Profit before tax | 1,335 | 1,619 | 1,055 | 1,133 | 1,063 | 1,465 |
| Tax | 338 | 407 | 274 | 360 | 364 | 437 |
| Tax rate % | 25.3% | 25.1% | 25.9% | 31.8% | 34.3% | 29.9% |
| Net profit | 997 | 1,212 | 781 | 772 | 699 | 1,027 |
| Profit to shareholders | 997 | 1,212 | 781 | 772 | 699 | 1,027 |
| Net margin % | 28.8% | 27.5% | 21.5% | 13.6% | 12.4% | 16.0% |
| EPS (₹) | 62.99 | 73.64 | 47.43 | 46.89 | 42.40 | 62.28 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Shareholders' equity · YoY (vs a year ago)
| ₹ Cr | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Sep 26 |
|---|---|---|---|---|---|
| Shareholders' equity | 7,959 | 8,724 | 9,151 | 10,358 | 10,686 |
| Long-term borrowings | 3.3 | 107 | 77.7 | 69.9 | 63.4 |
| Short-term borrowings | 0.6 | 213 | 192 | 173 | 156 |
| Total borrowings | 3.8 | 320 | 269 | 243 | 220 |
| Current liabilities | 729 | 1,398 | 1,565 | 1,608 | 1,714 |
| Fixed assets (PPE) | 1,559 | 3,541 | 3,751 | 4,052 | 3,970 |
| Inventories | 1,945 | 1,655 | 1,685 | 1,744 | 1,829 |
| Trade receivables | 871 | 1,559 | 1,517 | 1,891 | 1,927 |
| Cash & equivalents | 1,909 | 357 | 2,556 | 3,359 | 3,441 |
| Current assets | 6,901 | 5,645 | 6,783 | 7,527 | 7,872 |
| Total assets | 8,778 | 10,661 | 11,225 | 12,511 | 12,927 |
| Debt / equity | 0.00 | 0.04 | 0.03 | 0.02 | 0.02 |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
Operations · YoY (vs a year ago)
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 791 | 364 | 997 | 915 | 1,031 |
| Cash from investing | -1,003 | 1,208 | -1,757 | 1,705 | 138 |
| Cash from financing | 34.9 | 14.9 | -799 | -433 | -417 |
| Spent on fixed assets | -511 | -221 | -390 | -385 | -491 |
| Free cash flow | 279 | 143 | 607 | 530 | 541 |
| Net cash flow | -177 | 1,587 | -1,560 | 2,186 | 752 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Latest (30 Sep 2026)
- Promoter & group
- 45.75%
- Public (FIIs, mutual funds, retail…)
- 54.25%
- Promoter change, last quarter
- -6.02 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Dividend - Rs 20 Per Sh
- Dividend - Rs 18 Per Share
- Annual General Meeting/Dividend - Rs 20 Per Share
- Annual General Meeting
Board meetings
- GLAND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financi…
- the financial results for the period ended September 30, 2026
- GLAND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 10-Aug-2026 to inter-alia consider and approve the Unaudited Financi…
- the financial results for the period ended Jun 30, 2026
- the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend.
Filings with NSE
- General Updates
- Options to purchase securities
- Analysts/Institutional Investor Meet/Con. Call Updates
- Giving guarantees/indemnity/ becoming a surety for third party
- Appointment
- Copy of Newspaper Publication
- Shareholders meeting
Latest news
Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell' - CNBC TV18LinkedIn · 9 Nov, 12:57 pmGland Pharma Jumps 12% on Strong Q1, Broker UpgradesHDFC Sky · 11 Aug, 12:30 pmPharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Business Standard · 9 Nov, 12:23 pmGland Pharma 'Buy' retained by Nomura, target price raised to Rs3,750 on CDMO-led strategic resetMoneycontrol.com · 8 Oct, 12:30 pmDivis Laboratories, Gland Pharma, Sai Life Sciences shares hit 52-week highs; here's whyBusiness Today · 9 Nov, 11:35 amGland Pharma to Invest USD 21 Mn in US Expansion, Acquire 60% Stake in Novelstar PharmaMedical Dialogues · 5 Oct, 12:30 pmGland Pharma shares jump 12% to 52-week high after strong Q1 show; are key growth challenges over?Upstox · 10 Aug, 12:30 pmGland Pharma Share Price Today: Up 2.50% at Rs 3,035.60Univest · 28 Oct, 12:30 pmAbout
About Gland Pharma Limited
Gland Pharma Limited is listed on the NSE under the symbol GLAND and belongs to the Healthcare sector.
Company details
- Company name
- Gland Pharma Limited
- NSE symbol
- GLAND
- BSE scrip code
- 543245
- ISIN
- INE068V01023
- Listed on
- NSE, BSE
- Series
- EQ (normal equity)
- Listed on NSE since
- 20 Nov 2020
- Face value
- ₹1 per share
- Market lot
- 1 share
- Shares issued
- 16.50 crore
- Index
- NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Pharmaceuticals: Major
- Chair
- Srinivas Sadu
- Headquarters
- Hyderabad, Telangana, India
- Registered address
- Plot No.11& 84,TSIIC, Phase-IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, Telangana, India, 502307
- Founded
- 1978
- Employees
- 4,332
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- glandpharma.com
Peers
Other Healthcare stocks
-
LAURUSLABSLaurus Labs ₹2,220.00 -8.42%
-
DIVISLABDivi's Laboratories ₹11,080.00 -3.16%
-
MAXHEALTHMax Healthcare Institute ₹1,009.90 +6.63%
-
APOLLOHOSPApollo Hospitals Enterprise ₹8,771.00 +2.87%
-
NATCOPHARMNATCO Pharma ₹828.65 +2.25%
-
AUROPHARMAAurobindo Pharma ₹1,794.00 -1.60%
-
PPLPHARMAPiramal Pharma ₹244.93 +0.16%
-
FORTISFortis Healthcare ₹803.20 +5.13%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.